Introduction:

This study analyzed patients with metabolic syndrome and smokers treated with MV140 vaccine to prevent recurrent UTI.

Material and methods:

342 patients with recurrent UTI received MV140 vaccine between 2017 and 2020 in Barcelona, Spain. Variables analyzed: number of UTI at 3 and 6 months after MV140, age, gender, diabetes mellitus, body mass index, hypertension, total cholesterol, HDL-cholesterol, triglycerides and smoking. Patients were divided in Group 1: metabolic syndrome (2 or more variables), Group 2: no metabolic syndrome (less than 2 variables). On the other hand, patients were classified into smokers and non-smokers.

Results:

Mean age was 74, 82% were women. At the beginning, 88,9% had 3-5 UTI. Overall effectiveness with MV140 was 72.5% at 3 months and 56.2% at 6 months.

Group 1 (36%) presented 0-1 UTI in 78.9% and 62.6% at 3 and 6 months. In Group 2 (64%) the results were 69% and 52.5%. Comparing both groups, no statistically significant differences were observed (p=0,25, p=0,26). Smokers had 77.4% and 61.3% at 3 and 6 months, and non-smokers had 69.3% and 52.7%. There were also no statistically significant differences (p = 0.5, p = 0.36).

Group 1 and smoking (28,7%) had 82% at 3 months and 66.3% at 6 months. Group 2 and no smoking (71,3%) reached 60.3% and 52% at 3 and 6 months. There were no statistically significant differences between both groups.

Conclusions:

The overall efficacy of MV140 was high and safe, without side effects.

Patients with metabolic syndrome and smokers may benefit from this treatment.

        · abstract in Spanish     · text in English     · English ( pdf )